SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Goldman Sachs Cuts Bristol-Myers Squibb Price Target to $61 From $63

Goldman Sachs adjusted its price target on Bristol-Myers Squibb to $61 from $63.

BMY

Related stories